Brefeldin a reduces anchorage-independent survival, cancer stem cell potential and migration of MDA-MB-231 human breast cancer cells

Molecules

Volumn 19, Issue 11, 2014, Pages 17464-17477

  Tseng, Chao Neng ^a,b,c   Hong, Yi Ren ^c,d   Chang, Hsueh Wei ^a,c   Yu, Tsai Jung ^b   Hung, Ting Wei ^b   Hou, Ming Feng ^a   Yuan, Shyng Shiou F ^a   Cho, Chung Lung ^c   Liu, Chien Tsung ^b   Chiu, Chien Chih ^b   Huang, Chih Jen ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Breast cancer; Brefeldin A; Cancer stem cell; ER stress

Indexed keywords

BREFELDIN A; CD44 PROTEIN, HUMAN; GELATINASE B; HERMES ANTIGEN; MCL1 PROTEIN, HUMAN; MYCOTOXIN; PROTEIN BCL 2; PROTEIN MCL 1;

BREAST TUMOR; CANCER STEM CELL; CELL DEATH; CELL MOTION; CELL SURVIVAL; CULTURE TECHNIQUE; DOWN REGULATION; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PHENOTYPE; PROCEDURES; TUMOR CELL LINE;

ANTIGENS, CD44; BREAST NEOPLASMS; BREFELDIN A; CELL CULTURE TECHNIQUES; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 9; MYCOTOXINS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84912530504     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191117464     Document Type: Article

References (39)

1. Liu, S.; Dontu, G.; Wicha, M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005, 7, 86-95.
2. Korkaya, H.; Paulson, A.; Charafe-Jauffret, E.; Ginestier, C.; Brown, M.; Dutcher, J.; Clouthier, S.G.; Wicha, M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7, e1000121.
3. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea - A paradigm shift. Cancer Res. 2006, 66, 1883-1890.
4. Soltysova, A.; Altanerova, V.; Altaner, C. Cancer stem cells. Neoplasma 2005, 52, 435-440.
5. Ailles, L.E.; Weissman, I.L. Cancer stem cells in solid tumors. Curr. Opin. Biotechnol. 2007, 18, 460-466.
6. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265-273.
7. Yamashita, T.; Wang, X.W. Cancer stem cells in the development of liver cancer. J. Clin. Investig. 2013, 123, 1911-1918.
8. Peng, C.Y.; Fong, P.C.; Yu, C.C.; Tsai, W.C.; Tzeng, Y.M.; Chang, W.W. Methyl Antcinate A suppresses the population of cancer stem-like cells in MCF7 human breast cancer cell line. Molecules 2013, 18, 2539-2548.
9. Fillmore, C.M.; Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10, R25.
10. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; Daidone, M.G. Isolation and in Vitro Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties. Cancer Res. 2005, 65, 5506-5511.
11. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
12. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138, 645-59.
13. Tseng, C.N.; Huang, C.F.; Cho, C.L.; Chang, H.W.; Huang, C.W.; Chiu, C.C.; Chang, Y.F. Brefeldin a effectively inhibits cancer stem cell-like properties and MMP-9 activity in human colorectal cancer Colo 205 cells. Molecules 2013, 18, 10242-10253.
14. De la Mare, J.A.; Sterrenberg, J.N.; Sukhthankar, M.G.; Chiwakata, M.T.; Beukes, D.R.; Blatch, G.L.; Edkins, A.L. Assessment of potential anti-cancer stem cell activity of marine algal compounds using an in vitro mammosphere assay. Cancer Cell Int. 2013, 13, 39.
15. Tamura, G.; Ando, K.; Suzuki, S.; Takatsuki, A.; Arima, K. Antiviral activity of brefeldin A and verrucarin A. J. Antibiot. 1968, 21, 160-161.
16. Chardin, P.; McCormick, F. Brefeldin A: The advantage of being uncompetitive. Cell 1999, 97, 153-155.
17. Natsume, Y.; Ito, S.; Satsu, H.; Shimizu, M. Protective effect of quercetin on ER stress caused by calcium dynamics dysregulation in intestinal epithelial cells. Toxicology 2009, 258, 164-175.
18. Lee, M.S.; Chao, J.; Yen, J.C.; Lin, L.W.; Tsai, F.S.; Hsieh, M.T.; Peng, W.H.; Cheng, H.Y. Schizandrin protects primary rat cortical cell cultures from glutamate-induced apoptosis by inhibiting activation of the MAPK family and the mitochondria dependent pathway. Molecules 2012, 18, 354-372.
19. Simpson, C.D.; Anyiwe, K.; Schimmer, A.D. Anoikis resistance and tumor metastasis. Cancer Lett. 2008, 272, 177-185.
20. Farrar, W.L. Cancer Stem Cells; Cambridge University Press: New York, NY, USA, 2010; p. 171.
21. Radisky, E.S.; Radisky, D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland. Biol. Neoplasia 2010, 15, 201-212.
22. Lin, C.Y.; Tsai, P.H.; Kandaswami, C.C.; Lee, P.P.; Huang, C.J.; Hwang, J.J.; Lee, M.T. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. Cancer Sci. 2011, 102, 815-827.
23. Yu, Q.; Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14, 163-176.
24. Chetty, C.; Vanamala, S.K.; Gondi, C.S.; Dinh, D.H.; Gujrati, M.; Rao, J.S. MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell. Signal. 2012, 24, 549-559.
25. Chang, H.W.; Wang, H.C.; Chen, C.Y.; Hung, T.W.; Hou, M.F.; Yuan, S.S.; Huang, C.J.; Tseng, C.N. 5-azacytidine induces anoikis, inhibits mammosphere formation and reduces metalloproteinase 9 activity in MCF-7 human breast cancer cells. Molecules 2014, 19, 3149-3159.
26. Kopp, F.; Hermawan, A.; Oak, P.S.; Herrmann, A.; Wagner, E.; Roidl, A. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol. Cancer 2014, 13, 16.
27. Woods, N.T.; Yamaguchi, H.; Lee, F.Y.; Bhalla, K.N.; Wang, H.G. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 2007, 67, 10744-10752.
28. Sanchez-Tillo, E.; de Barrios, O.; Siles, L.; Cuatrecasas, M.; Castells, A.; Postigo, A. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. USA 2011, 108, 19204-19209.
29. Soini, Y.; Tuhkanen, H.; Sironen, R.; Virtanen, I.; Kataja, V.; Auvinen, P.; Mannermaa, A.; Kosma, V.M. Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer 2011, 11, 73.
30. Takeyama, Y.; Sato, M.; Horio, M.; Hase, T.; Yoshida, K.; Yokoyama, T.; Nakashima, H.; Hashimoto, N.; Sekido, Y.; Gazdar, A.F.; et al. Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett. 2010, 296, 216-224.
31. Aigner, K.; Dampier, B.; Descovich, L.; Mikula, M.; Sultan, A.; Schreiber, M.; Mikulits, W.; Brabletz, T.; Strand, D.; Obrist, P.; et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007, 26, 6979-6988.
32. Peinado, H.; Portillo, F.; Cano, A. Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 2004, 48, 365-375.
33. Babina, I.S.; McSherry, E.A.; Donatello, S.; Hill, A.D.; Hopkins, A.M. A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44. Breast Cancer Res. 2014, 16, R19.
34. Ponta, H.; Sherman, L.; Herrlich, P.A. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003, 4, 33-45.
35. Yakkundi, A.; McCallum, L.; O'Kane, A.; Dyer, H.; Worthington, J.; McKeen, H.D.; McClements, L.; Elliott, C.; McCarthy, H.O.; Hirst, D.G.; et al. The anti-migratory effects of FKBPL and its peptide derivative, AD-01: Regulation of CD44 and the cytoskeletal pathway. PLoS One 2013, 8, e55075.
36. Nickerson, N.K.; Mohammad, K.S.; Gilmore, J.L.; Crismore, E.; Bruzzaniti, A.; Guise, T.A.; Foley, J. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One 2012, 7, e30255.
37. Jechlinger, M.; Sommer, A.; Moriggl, R.; Seither, P.; Kraut, N.; Capodiecci, P.; Donovan, M.; Cordon-Cardo, C.; Beug, H.; Grunert, S. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Investig. 2006, 116, 1561-1570.
38. Harrison, H.; Simoes, B.M.; Rogerson, L.; Howell, S.J.; Landberg, G.; Clarke, R.B. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res. 2013, 15, R21.
39. Yu, Y.; Xiao, C.H.; Tan, L.D.; Wang, Q.S.; Li, X.Q.; Feng, Y.M. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br. J. Cancer 2014, 110, 724-732.